Drug Approval | May 20, 2023
Strides Puducherry facility receives EIR from USFDA
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
These initiatives aim to improve access to healthcare for rare disease patients
The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Subscribe To Our Newsletter & Stay Updated
